Note: Live price is not available for this stock. Showing closing price. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
AUROPHARMA Stock Analysis
Views
Red Flags
Positive
Stock is reasonably valued and PE TTM is at a discount to industry median
Strong price momentum
High and stable operating margin
Low Debt to Equity, not much change from last year
Company is net cash
Negative
Analysts have been downgrading forward EPS estimates
Moderate ROE but declining trend
Low revenue growth and in line with median growth of industry
Low EPS growth and in line with median growth of industry
Low dividend yield
Neutral
Company's earnings are of moderate quality
No red flags found!
No significant red flags found in the stock.
Snapshot
See detailed analysis
AUROPHARMA Shareholding Pattern
An overview of who owns the company. Click on chart icon to view historical movement.
AUROPHARMA Bulk, Block & Insider Trades
AUROPHARMA Dividends, Splits & Bonus
Dividend Events
Capital Change Events
Bonus
Stock split
Others
Bonus(1 new shares for 1 existing shares) Ex-date: 20th Jul 2015 Announced on: 28th May 2015
Bonus(1 new shares for 1 existing shares) Ex-date: 7th Mar 2000 Announced on: 7th Mar 2000
Bonus(1 new shares for 1 existing shares)Bonus issue of 1:1. Ex-date: 26th Oct 1998 Announced on: 30th Jun 1998
Stock split(1 : 5)EGM 23 December 2010. BOD 03 November 2010. Nominal value changes from INR 5 to INR 1. Ex-date: 10th Feb 2011 Announced on: 3rd Nov 2010
Stock split(1 : 2) Ex-date: 23rd Oct 2003 Announced on: 22nd Sep 2003
Share Buyback"On Market Tender Offer. Total Amount Returned INR 7500000000. As of 21 August 2024 Shares repurchased 5136986." Ex-date: 30th Jul 2024 Announced on: 18th Jul 2024
Company Profile
Aurobindo Pharma Limited is an India-based pharmaceutical company. The Company is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, branded pharmaceuticals, generic pharmaceuticals, and related services. Its key therapeutic segments include Central nervous syst... Read More
Key personnel
Shri. Mangalam Ramasubramanian KumarD
Non-Executive Independent Chairman of the Board
Mr. K. Nityananda ReddyD
Executive Vice Chairman of the Board, Managing Director, Promoter
Mr. Santhanam Subramanian
Chief Financial Officer
Mr. B. Adi Reddy
Compliance Officer, Company Secretary
Mr. Mettu Madan Mohan ReddyD
Whole-Time Director
Dr. Satakarni MakkapatiD
Non-Executive Non-Independent Director
Mr. Penaka Sarath Chandra ReddyD
Non-Executive Non-Independent Director
Mr. P.V. Ramaprasad ReddyD
Non-Executive Director, Promoter
View all
Incorporated on
Last Annual
Last Interim
No. of Employees
IPO date
Free Float
Website
Phone no.
Address
Frequently asked questions
What is the current share price of Aurobindo Pharma Ltd.?
The current share price of Aurobindo Pharma Ltd. is ₹ 1,198.60 as of 09 Jan 2026.
What is the PE ratio of Aurobindo Pharma Ltd.?
The Price-to-Earnings (PE) ratio of Aurobindo Pharma Ltd. is 20.34 as of the latest financial data.
What is the ROE and ROCE of Aurobindo Pharma Ltd.?
Aurobindo Pharma Ltd. has a Return on Equity (ROE) of 10.38% and a Return on Capital Employed (ROCE) of 12.13% as per the latest financial reports.
What is the market cap of Aurobindo Pharma Ltd.?
The market capitalization of Aurobindo Pharma Ltd. stands at ₹ 69,614.90 Cr.
What is the dividend yield of Aurobindo Pharma Ltd.?
The dividend yield of Aurobindo Pharma Ltd. is 0.33% based on the current market price.
What is the RSI of Aurobindo Pharma Ltd.?
The Relative Strength Index (RSI) of Aurobindo Pharma Ltd. is 48.80.
What is the FII and DII holding in Aurobindo Pharma Ltd.?
Foreign Institutional Investors (FII) hold 14.21% and Domestic Institutional Investors (DII) hold 25.17% of Aurobindo Pharma Ltd. shares.
What sector does Aurobindo Pharma Ltd. belong to?
Aurobindo Pharma Ltd. operates in the Healthcare sector.
What is the beta of Aurobindo Pharma Ltd. stock?
The beta of Aurobindo Pharma Ltd. stock is 1.15, indicating its volatility relative to the broader market.
